1. BRM270, a Compound from Natural Plant Extracts, Inhibits Glioblastoma Stem Cell Properties and Glioblastoma Recurrence
- Author
-
Sunyoung Seo, Hee Young Jeon, Seok Won Ham, Jun Kyum Kim, Xiong Jin, Hyunggee Kim, Cheol Gyu Park, Jung Yun Kim, Sang Hun Choi, Seon Yong Lee, Eun Jung Kim, and Kiyoung Eun
- Subjects
0301 basic medicine ,endocrine system ,Medicine (miscellaneous) ,Mice, Nude ,Apoptosis ,Drug resistance ,Pharmacology ,Biology ,03 medical and health sciences ,Mice ,In vivo ,medicine ,Animals ,Humans ,Cell Proliferation ,Nutrition and Dietetics ,Cell growth ,Brain Neoplasms ,Plant Extracts ,fungi ,Chemoradiotherapy ,medicine.disease ,Antineoplastic Agents, Phytogenic ,Combined Modality Therapy ,In vitro ,nervous system diseases ,Concurrent chemoradiotherapy ,030104 developmental biology ,Cancer research ,Neoplastic Stem Cells ,Tumor growth inhibition ,Stem cell ,Glioblastoma - Abstract
Glioblastoma multiforme (GBM) is one of the most aggressive and lethal human brain tumors, and the median survival of patients with GBM is only 14 months. Glioblastoma stem cells (GSCs) are regarded as a main cause of GBM recurrence, because of their self-renewal and drug resistance properties. Therefore, targeting GSCs is an important therapeutic strategy for GBM. In this study, we show the effects of BRM270, a compound from natural plant extracts, on GSCs in vitro and GBM recurrence in vivo. BRM270 induced apoptotic cell death and inhibited cell growth and “stemness” both in vitro and in vivo. Combining BRM270 treatment with concurrent chemoradiotherapy (CCRT) dramatically increased mice survival and tumor growth inhibition. Taken together, our results suggested that BRM270 synergizes with CCRT as a therapeutic agent to target GSCs.
- Published
- 2017